<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Integrated Cascade-Inflammation-Mitochondrial (ICIM) Theory of Alzheimer's Disease - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-546</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-546</p>
                <p><strong>Name:</strong> Integrated Cascade-Inflammation-Mitochondrial (ICIM) Theory of Alzheimer's Disease</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the cause of Alzheimer's disease and how it can be effectively detected, based on the following results.</p>
                <p><strong>Description:</strong> The ICIM theory posits that Alzheimer's disease (AD) arises from a self-reinforcing, multifactorial network involving amyloid-beta (Aβ) accumulation, tau hyperphosphorylation, chronic neuroinflammation, and mitochondrial dysfunction. Rather than a strictly linear cascade, these processes interact in positive feedback loops, where each can initiate or amplify the others. The earliest detectable changes may be metabolic (mitochondrial/energy deficits and subtle inflammation), which then facilitate Aβ and tau pathology. The interplay between these axes, modulated by genetic and environmental risk factors, determines the rate and regional pattern of neurodegeneration. This model predicts that effective detection and intervention require multi-modal, stage-specific biomarker panels that capture not only Aβ and tau, but also metabolic, inflammatory, and synaptic dysfunction.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2024</p>
                <p><strong>Knowledge Cutoff Month:</strong> 6</p>
                <p><strong>Base Model:</strong> openai/gpt-4.1-2025-04-14</p>
            </div>
        </div>

        <div class="section">
            <h2>Theory (Derived From)</h2>
            <p><strong>Derived From:</strong> <span class="empty-note">None</span></p>
            <p><strong>Change Log:</strong> <span class="empty-note">No change log entries.</span></p>
        </div>

        <div class="section">
            <h2>Evaluations of this Theory</h2>
            <p class="empty-note">No evaluations of this theory.</p>
        </div>

        <div class="section">
            <h2>Theory (Details)</h2>

            <h3>Theory Statements</h3>
            <h3>Statement 0: Multifactorial Feedback Cascade Law (qualitative)</h3>
<table>
<thead> 
<tr><th style="width: 10%;">Condition</th><th style="width: 90%;">Details</th></tr>
</thead>
<tbody>
<tr>
    <td><strong>IF</strong></td>
    <td>
        <div>&#8226; brain &#8594; exhibits &#8594; chronic mitochondrial dysfunction<span style="color: #888888;">, and</span></div>
        <div>&#8226; brain &#8594; exhibits &#8594; chronic low-grade neuroinflammation</div>
    </td>
</tr>
<tr>
    <td><strong>THEN</strong></td>
    <td>
        <div>&#8226; brain &#8594; increases_risk_of &#8594; Aβ aggregation and tau hyperphosphorylation<span style="color: #888888;">, and</span></div>
        <div>&#8226; Aβ and tau pathology &#8594; further_exacerbate &#8594; mitochondrial dysfunction and neuroinflammation</div>
    </td>
</tr>
</tbody>
</table>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Mitochondrial dysfunction and neuroinflammation are both cited as contributors to AD pathogenesis, and each is shown to promote Aβ and tau pathology, while Aβ and tau can further impair mitochondria and activate glia. <a href="../results/extraction-result-3933.html#e3933.2" class="evidence-link">[e3933.2]</a> <a href="../results/extraction-result-3933.html#e3933.3" class="evidence-link">[e3933.3]</a> <a href="../results/extraction-result-3915.html#e3915.2" class="evidence-link">[e3915.2]</a> <a href="../results/extraction-result-3938.html#e3938.2" class="evidence-link">[e3938.2]</a> <a href="../results/extraction-result-3916.html#e3916.2" class="evidence-link">[e3916.2]</a> <a href="../results/extraction-result-3942.html#e3942.3" class="evidence-link">[e3942.3]</a> <a href="../results/extraction-result-3933.html#e3933.4" class="evidence-link">[e3933.4]</a> <a href="../results/extraction-result-3933.html#e3933.10" class="evidence-link">[e3933.10]</a> <a href="../results/extraction-result-3916.html#e3916.8" class="evidence-link">[e3916.8]</a> <a href="../results/extraction-result-3913.html#e3913.10" class="evidence-link">[e3913.10]</a> <a href="../results/extraction-result-3913.html#e3913.11" class="evidence-link">[e3913.11]</a> <a href="../results/extraction-result-3932.html#e3932.5" class="evidence-link">[e3932.5]</a> <a href="../results/extraction-result-3933.html#e3933.1" class="evidence-link">[e3933.1]</a> <a href="../results/extraction-result-3933.html#e3933.8" class="evidence-link">[e3933.8]</a> <a href="../results/extraction-result-3938.html#e3938.0" class="evidence-link">[e3938.0]</a> <a href="../results/extraction-result-3938.html#e3938.4" class="evidence-link">[e3938.4]</a> <a href="../results/extraction-result-3914.html#e3914.10" class="evidence-link">[e3914.10]</a> <a href="../results/extraction-result-3941.html#e3941.4" class="evidence-link">[e3941.4]</a> <a href="../results/extraction-result-3941.html#e3941.3" class="evidence-link">[e3941.3]</a> </li>
</ol>            <h4>Existing Law Comparison</h4>
            <p class="empty-note">No existing law comparison provided.</p>
            <h3>Statement 1: Stage-Dependent Biomarker Law (qualitative)</h3>
<table>
<thead> 
<tr><th style="width: 10%;">Condition</th><th style="width: 90%;">Details</th></tr>
</thead>
<tbody>
<tr>
    <td><strong>IF</strong></td>
    <td>
        <div>&#8226; individual &#8594; is_in &#8594; preclinical or prodromal AD stage</div>
    </td>
</tr>
<tr>
    <td><strong>THEN</strong></td>
    <td>
        <div>&#8226; biomarker_panel &#8594; should_include &#8594; metabolic (FDG-PET, MRS), inflammatory (GFAP, cytokines), and synaptic (NfL, neurogranin) markers in addition to Aβ and tau</div>
    </td>
</tr>
</tbody>
</table>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>FDG-PET, MRS, NfL, neurogranin, and inflammatory markers are all shown to be altered early in AD and can precede overt atrophy or clinical symptoms. Early metabolic and inflammatory changes are detectable in preclinical and prodromal stages. <a href="../results/extraction-result-3897.html#e3897.1" class="evidence-link">[e3897.1]</a> <a href="../results/extraction-result-3907.html#e3907.4" class="evidence-link">[e3907.4]</a> <a href="../results/extraction-result-3942.html#e3942.10" class="evidence-link">[e3942.10]</a> <a href="../results/extraction-result-3933.html#e3933.10" class="evidence-link">[e3933.10]</a> <a href="../results/extraction-result-3933.html#e3933.4" class="evidence-link">[e3933.4]</a> <a href="../results/extraction-result-3915.html#e3915.2" class="evidence-link">[e3915.2]</a> <a href="../results/extraction-result-3932.html#e3932.4" class="evidence-link">[e3932.4]</a> <a href="../results/extraction-result-3933.html#e3933.8" class="evidence-link">[e3933.8]</a> <a href="../results/extraction-result-3938.html#e3938.0" class="evidence-link">[e3938.0]</a> <a href="../results/extraction-result-3938.html#e3938.5" class="evidence-link">[e3938.5]</a> <a href="../results/extraction-result-3938.html#e3938.9" class="evidence-link">[e3938.9]</a> <a href="../results/extraction-result-3933.html#e3933.1" class="evidence-link">[e3933.1]</a> <a href="../results/extraction-result-3933.html#e3933.2" class="evidence-link">[e3933.2]</a> <a href="../results/extraction-result-3933.html#e3933.3" class="evidence-link">[e3933.3]</a> <a href="../results/extraction-result-3933.html#e3933.11" class="evidence-link">[e3933.11]</a> <a href="../results/extraction-result-3933.html#e3933.12" class="evidence-link">[e3933.12]</a> <a href="../results/extraction-result-3932.html#e3932.5" class="evidence-link">[e3932.5]</a> <a href="../results/extraction-result-3933.html#e3933.8" class="evidence-link">[e3933.8]</a> <a href="../results/extraction-result-3938.html#e3938.4" class="evidence-link">[e3938.4]</a> <a href="../results/extraction-result-3914.html#e3914.10" class="evidence-link">[e3914.10]</a> <a href="../results/extraction-result-3941.html#e3941.4" class="evidence-link">[e3941.4]</a> <a href="../results/extraction-result-3941.html#e3941.3" class="evidence-link">[e3941.3]</a> <a href="../results/extraction-result-3916.html#e3916.8" class="evidence-link">[e3916.8]</a> <a href="../results/extraction-result-3913.html#e3913.10" class="evidence-link">[e3913.10]</a> <a href="../results/extraction-result-3913.html#e3913.11" class="evidence-link">[e3913.11]</a> <a href="../results/extraction-result-3932.html#e3932.5" class="evidence-link">[e3932.5]</a> <a href="../results/extraction-result-3933.html#e3933.1" class="evidence-link">[e3933.1]</a> <a href="../results/extraction-result-3933.html#e3933.8" class="evidence-link">[e3933.8]</a> <a href="../results/extraction-result-3938.html#e3938.0" class="evidence-link">[e3938.0]</a> </li>
</ol>            <h4>Existing Law Comparison</h4>
            <p class="empty-note">No existing law comparison provided.</p>
            <h3>Statement 2: Positive Feedback Loop Law (qualitative)</h3>
<table>
<thead> 
<tr><th style="width: 10%;">Condition</th><th style="width: 90%;">Details</th></tr>
</thead>
<tbody>
<tr>
    <td><strong>IF</strong></td>
    <td>
        <div>&#8226; Aβ aggregation &#8594; is_present &#8594; in brain<span style="color: #888888;">, and</span></div>
        <div>&#8226; tau hyperphosphorylation &#8594; is_present &#8594; in brain</div>
    </td>
</tr>
<tr>
    <td><strong>THEN</strong></td>
    <td>
        <div>&#8226; Aβ and tau &#8594; amplify &#8594; neuroinflammation and mitochondrial dysfunction<span style="color: #888888;">, and</span></div>
        <div>&#8226; neuroinflammation and mitochondrial dysfunction &#8594; amplify &#8594; Aβ and tau pathology</div>
    </td>
</tr>
</tbody>
</table>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Aβ and tau pathology are shown to activate microglia/astrocytes and impair mitochondria, while inflammation and mitochondrial dysfunction promote further Aβ and tau accumulation. <a href="../results/extraction-result-3933.html#e3933.2" class="evidence-link">[e3933.2]</a> <a href="../results/extraction-result-3933.html#e3933.3" class="evidence-link">[e3933.3]</a> <a href="../results/extraction-result-3938.html#e3938.2" class="evidence-link">[e3938.2]</a> <a href="../results/extraction-result-3915.html#e3915.2" class="evidence-link">[e3915.2]</a> <a href="../results/extraction-result-3933.html#e3933.1" class="evidence-link">[e3933.1]</a> <a href="../results/extraction-result-3933.html#e3933.4" class="evidence-link">[e3933.4]</a> <a href="../results/extraction-result-3933.html#e3933.10" class="evidence-link">[e3933.10]</a> <a href="../results/extraction-result-3916.html#e3916.2" class="evidence-link">[e3916.2]</a> <a href="../results/extraction-result-3942.html#e3942.3" class="evidence-link">[e3942.3]</a> <a href="../results/extraction-result-3933.html#e3933.8" class="evidence-link">[e3933.8]</a> <a href="../results/extraction-result-3938.html#e3938.0" class="evidence-link">[e3938.0]</a> <a href="../results/extraction-result-3938.html#e3938.4" class="evidence-link">[e3938.4]</a> <a href="../results/extraction-result-3914.html#e3914.10" class="evidence-link">[e3914.10]</a> <a href="../results/extraction-result-3941.html#e3941.4" class="evidence-link">[e3941.4]</a> <a href="../results/extraction-result-3941.html#e3941.3" class="evidence-link">[e3941.3]</a> <a href="../results/extraction-result-3916.html#e3916.8" class="evidence-link">[e3916.8]</a> <a href="../results/extraction-result-3913.html#e3913.10" class="evidence-link">[e3913.10]</a> <a href="../results/extraction-result-3913.html#e3913.11" class="evidence-link">[e3913.11]</a> </li>
</ol>            <h4>Existing Law Comparison</h4>
            <p class="empty-note">No existing law comparison provided.</p>
            <h3>Statement 3: Non-Linear Progression Law (qualitative)</h3>
<table>
<thead> 
<tr><th style="width: 10%;">Condition</th><th style="width: 90%;">Details</th></tr>
</thead>
<tbody>
<tr>
    <td><strong>IF</strong></td>
    <td>
        <div>&#8226; individual &#8594; has &#8594; genetic or environmental risk factors (e.g., APOE4, vascular/metabolic comorbidities)</div>
    </td>
</tr>
<tr>
    <td><strong>THEN</strong></td>
    <td>
        <div>&#8226; cascade_interactions &#8594; are &#8594; accelerated and regionally variable</div>
    </td>
</tr>
</tbody>
</table>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>APOE4, vascular, and metabolic risk factors are shown to modulate the rate and pattern of Aβ, tau, and neurodegeneration, and interact with inflammation and mitochondrial dysfunction. <a href="../results/extraction-result-3938.html#e3938.4" class="evidence-link">[e3938.4]</a> <a href="../results/extraction-result-3914.html#e3914.10" class="evidence-link">[e3914.10]</a> <a href="../results/extraction-result-3941.html#e3941.4" class="evidence-link">[e3941.4]</a> <a href="../results/extraction-result-3941.html#e3941.3" class="evidence-link">[e3941.3]</a> <a href="../results/extraction-result-3916.html#e3916.8" class="evidence-link">[e3916.8]</a> <a href="../results/extraction-result-3913.html#e3913.10" class="evidence-link">[e3913.10]</a> <a href="../results/extraction-result-3913.html#e3913.11" class="evidence-link">[e3913.11]</a> <a href="../results/extraction-result-3932.html#e3932.5" class="evidence-link">[e3932.5]</a> <a href="../results/extraction-result-3933.html#e3933.1" class="evidence-link">[e3933.1]</a> <a href="../results/extraction-result-3933.html#e3933.2" class="evidence-link">[e3933.2]</a> <a href="../results/extraction-result-3933.html#e3933.3" class="evidence-link">[e3933.3]</a> <a href="../results/extraction-result-3933.html#e3933.4" class="evidence-link">[e3933.4]</a> <a href="../results/extraction-result-3933.html#e3933.10" class="evidence-link">[e3933.10]</a> <a href="../results/extraction-result-3933.html#e3933.11" class="evidence-link">[e3933.11]</a> <a href="../results/extraction-result-3933.html#e3933.12" class="evidence-link">[e3933.12]</a> <a href="../results/extraction-result-3938.html#e3938.0" class="evidence-link">[e3938.0]</a> </li>
</ol>            <h4>Existing Law Comparison</h4>
            <p class="empty-note">No existing law comparison provided.</p>
            <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Individuals with early metabolic deficits (e.g., reduced FDG-PET uptake or MRS NAA/mI changes) but no overt Aβ or tau pathology will show increased risk of subsequent Aβ/tau accumulation and cognitive decline.</li>
                <li>Simultaneous measurement of metabolic, inflammatory, and synaptic markers will improve early AD detection and staging compared to Aβ/tau markers alone.</li>
                <li>Interventions that target both mitochondrial function and neuroinflammation will slow or prevent the progression of Aβ and tau pathology more effectively than targeting Aβ or tau alone.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>In individuals with strong mitochondrial or inflammatory dysfunction but no detectable Aβ or tau, AD-like neurodegeneration and cognitive decline may still occur, suggesting a possible Aβ/tau-independent pathway.</li>
                <li>Longitudinal multi-modal biomarker studies will reveal subtypes of AD with distinct initial drivers (e.g., inflammation-first, mitochondria-first, Aβ-first), each with different progression rates and responses to therapy.</li>
                <li>Early intervention with anti-inflammatory and mitochondrial-supportive agents in at-risk but Aβ/tau-negative individuals will prevent or delay the onset of Aβ/tau pathology and clinical symptoms.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If individuals with chronic mitochondrial dysfunction and neuroinflammation do not develop Aβ or tau pathology or cognitive decline at higher rates than controls, the feedback cascade model would be challenged.</li>
                <li>If interventions that normalize mitochondrial function and reduce inflammation do not alter the trajectory of Aβ/tau accumulation or neurodegeneration, the theory's central feedback loop would be called into question.</li>
                <li>If early metabolic and inflammatory changes are not detectable before Aβ/tau pathology in longitudinal studies, the theory's prediction of early non-amyloid/tau drivers would be undermined.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The role of rare genetic mutations (e.g., familial AD) that cause Aβ overproduction independent of inflammation or mitochondria is not fully explained by this model. <a href="../results/extraction-result-3941.html#e3941.1" class="evidence-link">[e3941.1]</a> </li>
    <li>Cases of AD with minimal or absent Aβ/tau pathology but clear clinical syndrome (so-called 'suspected non-Alzheimer's pathophysiology', SNAP) are not fully addressed. <a href="../results/extraction-result-3932.html#e3932.4" class="evidence-link">[e3932.4]</a> </li>
</ol>            <h3>Existing Theory Comparison</h3>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
            <p><strong>Explanation:</strong> No explanation provided.</p>
            <p><strong>References:</strong> <ul>
    <li>Selkoe & Hardy (2016) The amyloid hypothesis of Alzheimer's disease at 25 years [classic amyloid cascade hypothesis]</li>
    <li>De Strooper & Karran (2016) The Cellular Phase of Alzheimer's Disease [emphasizes multi-cellular, multi-factorial interactions]</li>
    <li>Swerdlow (2018) Mitochondria and Mitochondrial Cascades in Alzheimer's Disease [mitochondrial cascade hypothesis]</li>
    <li>Heneka et al. (2015) Neuroinflammation in Alzheimer's disease [neuroinflammatory hypothesis]</li>
    <li>This theory is novel in explicitly integrating these axes into a self-reinforcing, non-linear feedback network and in predicting that metabolic/inflammatory changes can precede and drive Aβ/tau pathology in some cases.</li>
</ul>
        </div>

        <div class="section">
            <h2>Theory Components (Debug)</h2>
            <pre><code>{
    "theory_name": "Integrated Cascade-Inflammation-Mitochondrial (ICIM) Theory of Alzheimer's Disease",
    "theory_description": "The ICIM theory posits that Alzheimer's disease (AD) arises from a self-reinforcing, multifactorial network involving amyloid-beta (Aβ) accumulation, tau hyperphosphorylation, chronic neuroinflammation, and mitochondrial dysfunction. Rather than a strictly linear cascade, these processes interact in positive feedback loops, where each can initiate or amplify the others. The earliest detectable changes may be metabolic (mitochondrial/energy deficits and subtle inflammation), which then facilitate Aβ and tau pathology. The interplay between these axes, modulated by genetic and environmental risk factors, determines the rate and regional pattern of neurodegeneration. This model predicts that effective detection and intervention require multi-modal, stage-specific biomarker panels that capture not only Aβ and tau, but also metabolic, inflammatory, and synaptic dysfunction.",
    "theory_statements": [
        {
            "law": {
                "law_name": "Multifactorial Feedback Cascade Law",
                "if": [
                    {
                        "subject": "brain",
                        "relation": "exhibits",
                        "object": "chronic mitochondrial dysfunction"
                    },
                    {
                        "subject": "brain",
                        "relation": "exhibits",
                        "object": "chronic low-grade neuroinflammation"
                    }
                ],
                "then": [
                    {
                        "subject": "brain",
                        "relation": "increases_risk_of",
                        "object": "Aβ aggregation and tau hyperphosphorylation"
                    },
                    {
                        "subject": "Aβ and tau pathology",
                        "relation": "further_exacerbate",
                        "object": "mitochondrial dysfunction and neuroinflammation"
                    }
                ],
                "supporting_evidence": [
                    {
                        "text": "Mitochondrial dysfunction and neuroinflammation are both cited as contributors to AD pathogenesis, and each is shown to promote Aβ and tau pathology, while Aβ and tau can further impair mitochondria and activate glia.",
                        "uuids": [
                            "e3933.2",
                            "e3933.3",
                            "e3915.2",
                            "e3938.2",
                            "e3916.2",
                            "e3942.3",
                            "e3933.4",
                            "e3933.10",
                            "e3916.8",
                            "e3913.10",
                            "e3913.11",
                            "e3932.5",
                            "e3933.1",
                            "e3933.8",
                            "e3938.0",
                            "e3938.4",
                            "e3914.10",
                            "e3941.4",
                            "e3941.3"
                        ]
                    }
                ],
                "qual_or_quant": "qualitative"
            }
        },
        {
            "law": {
                "law_name": "Stage-Dependent Biomarker Law",
                "if": [
                    {
                        "subject": "individual",
                        "relation": "is_in",
                        "object": "preclinical or prodromal AD stage"
                    }
                ],
                "then": [
                    {
                        "subject": "biomarker_panel",
                        "relation": "should_include",
                        "object": "metabolic (FDG-PET, MRS), inflammatory (GFAP, cytokines), and synaptic (NfL, neurogranin) markers in addition to Aβ and tau"
                    }
                ],
                "supporting_evidence": [
                    {
                        "text": "FDG-PET, MRS, NfL, neurogranin, and inflammatory markers are all shown to be altered early in AD and can precede overt atrophy or clinical symptoms. Early metabolic and inflammatory changes are detectable in preclinical and prodromal stages.",
                        "uuids": [
                            "e3897.1",
                            "e3907.4",
                            "e3942.10",
                            "e3933.10",
                            "e3933.4",
                            "e3915.2",
                            "e3932.4",
                            "e3933.8",
                            "e3938.0",
                            "e3938.5",
                            "e3938.9",
                            "e3933.1",
                            "e3933.2",
                            "e3933.3",
                            "e3933.11",
                            "e3933.12",
                            "e3932.5",
                            "e3933.8",
                            "e3938.4",
                            "e3914.10",
                            "e3941.4",
                            "e3941.3",
                            "e3916.8",
                            "e3913.10",
                            "e3913.11",
                            "e3932.5",
                            "e3933.1",
                            "e3933.8",
                            "e3938.0"
                        ]
                    }
                ],
                "qual_or_quant": "qualitative"
            }
        },
        {
            "law": {
                "law_name": "Positive Feedback Loop Law",
                "if": [
                    {
                        "subject": "Aβ aggregation",
                        "relation": "is_present",
                        "object": "in brain"
                    },
                    {
                        "subject": "tau hyperphosphorylation",
                        "relation": "is_present",
                        "object": "in brain"
                    }
                ],
                "then": [
                    {
                        "subject": "Aβ and tau",
                        "relation": "amplify",
                        "object": "neuroinflammation and mitochondrial dysfunction"
                    },
                    {
                        "subject": "neuroinflammation and mitochondrial dysfunction",
                        "relation": "amplify",
                        "object": "Aβ and tau pathology"
                    }
                ],
                "supporting_evidence": [
                    {
                        "text": "Aβ and tau pathology are shown to activate microglia/astrocytes and impair mitochondria, while inflammation and mitochondrial dysfunction promote further Aβ and tau accumulation.",
                        "uuids": [
                            "e3933.2",
                            "e3933.3",
                            "e3938.2",
                            "e3915.2",
                            "e3933.1",
                            "e3933.4",
                            "e3933.10",
                            "e3916.2",
                            "e3942.3",
                            "e3933.8",
                            "e3938.0",
                            "e3938.4",
                            "e3914.10",
                            "e3941.4",
                            "e3941.3",
                            "e3916.8",
                            "e3913.10",
                            "e3913.11"
                        ]
                    }
                ],
                "qual_or_quant": "qualitative"
            }
        },
        {
            "law": {
                "law_name": "Non-Linear Progression Law",
                "if": [
                    {
                        "subject": "individual",
                        "relation": "has",
                        "object": "genetic or environmental risk factors (e.g., APOE4, vascular/metabolic comorbidities)"
                    }
                ],
                "then": [
                    {
                        "subject": "cascade_interactions",
                        "relation": "are",
                        "object": "accelerated and regionally variable"
                    }
                ],
                "supporting_evidence": [
                    {
                        "text": "APOE4, vascular, and metabolic risk factors are shown to modulate the rate and pattern of Aβ, tau, and neurodegeneration, and interact with inflammation and mitochondrial dysfunction.",
                        "uuids": [
                            "e3938.4",
                            "e3914.10",
                            "e3941.4",
                            "e3941.3",
                            "e3916.8",
                            "e3913.10",
                            "e3913.11",
                            "e3932.5",
                            "e3933.1",
                            "e3933.2",
                            "e3933.3",
                            "e3933.4",
                            "e3933.10",
                            "e3933.11",
                            "e3933.12",
                            "e3938.0"
                        ]
                    }
                ],
                "qual_or_quant": "qualitative"
            }
        }
    ],
    "new_predictions_likely": [
        "Individuals with early metabolic deficits (e.g., reduced FDG-PET uptake or MRS NAA/mI changes) but no overt Aβ or tau pathology will show increased risk of subsequent Aβ/tau accumulation and cognitive decline.",
        "Simultaneous measurement of metabolic, inflammatory, and synaptic markers will improve early AD detection and staging compared to Aβ/tau markers alone.",
        "Interventions that target both mitochondrial function and neuroinflammation will slow or prevent the progression of Aβ and tau pathology more effectively than targeting Aβ or tau alone."
    ],
    "new_predictions_unknown": [
        "In individuals with strong mitochondrial or inflammatory dysfunction but no detectable Aβ or tau, AD-like neurodegeneration and cognitive decline may still occur, suggesting a possible Aβ/tau-independent pathway.",
        "Longitudinal multi-modal biomarker studies will reveal subtypes of AD with distinct initial drivers (e.g., inflammation-first, mitochondria-first, Aβ-first), each with different progression rates and responses to therapy.",
        "Early intervention with anti-inflammatory and mitochondrial-supportive agents in at-risk but Aβ/tau-negative individuals will prevent or delay the onset of Aβ/tau pathology and clinical symptoms."
    ],
    "negative_experiments": [
        "If individuals with chronic mitochondrial dysfunction and neuroinflammation do not develop Aβ or tau pathology or cognitive decline at higher rates than controls, the feedback cascade model would be challenged.",
        "If interventions that normalize mitochondrial function and reduce inflammation do not alter the trajectory of Aβ/tau accumulation or neurodegeneration, the theory's central feedback loop would be called into question.",
        "If early metabolic and inflammatory changes are not detectable before Aβ/tau pathology in longitudinal studies, the theory's prediction of early non-amyloid/tau drivers would be undermined."
    ],
    "unaccounted_for": [
        {
            "text": "The role of rare genetic mutations (e.g., familial AD) that cause Aβ overproduction independent of inflammation or mitochondria is not fully explained by this model.",
            "uuids": [
                "e3941.1"
            ]
        },
        {
            "text": "Cases of AD with minimal or absent Aβ/tau pathology but clear clinical syndrome (so-called 'suspected non-Alzheimer's pathophysiology', SNAP) are not fully addressed.",
            "uuids": [
                "e3932.4"
            ]
        }
    ],
    "conflicting_evidence": [
        {
            "text": "Some individuals with high Aβ/tau burden do not develop clinical AD, suggesting that the feedback cascade may not be sufficient for disease expression.",
            "uuids": [
                "e4028.0",
                "e4030.0",
                "e3918.0",
                "e3929.0",
                "e3938.0",
                "e4031.0",
                "e4031.7"
            ]
        }
    ],
    "special_cases": [
        "Familial AD due to APP/PSEN mutations may follow a more linear Aβ-driven cascade, with less prominent early metabolic/inflammatory changes.",
        "Individuals with strong vascular or metabolic comorbidities may develop mixed or atypical AD phenotypes, with variable contributions from each axis."
    ],
    "existing_theory": {
        "likely_classification": "closely-related-to-existing",
        "references": [
            "Selkoe & Hardy (2016) The amyloid hypothesis of Alzheimer's disease at 25 years [classic amyloid cascade hypothesis]",
            "De Strooper & Karran (2016) The Cellular Phase of Alzheimer's Disease [emphasizes multi-cellular, multi-factorial interactions]",
            "Swerdlow (2018) Mitochondria and Mitochondrial Cascades in Alzheimer's Disease [mitochondrial cascade hypothesis]",
            "Heneka et al. (2015) Neuroinflammation in Alzheimer's disease [neuroinflammatory hypothesis]",
            "This theory is novel in explicitly integrating these axes into a self-reinforcing, non-linear feedback network and in predicting that metabolic/inflammatory changes can precede and drive Aβ/tau pathology in some cases."
        ]
    },
    "theory_type_general_specific": "general",
    "reflected_from_theory_index": 0,
    "version": "built-theory-from-results-single-theory-reflection2-nov13-2025",
    "type": "general"
}</code></pre>
        </div>
    </div>
</body>
</html>